bloating. Diseases of oesophagus,stomach and duodenum
Conditions
Interventions
Intervention 1: Control group:Our placebo is corn starch oral capsules which should be taken three times daily,one capsule after every meal for a month. Intervention 2: Intervention group:Our drug i
Placebo
Treatment - Drugs
Control group:Our placebo is corn starch oral capsules which should be taken three times daily,one capsule after every meal for a month
Intervention group:Our drug is carum capticum seed oral capsules which should be taken three times daily,one capsule after every meal for a month
Sponsors
Vice chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 49 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age of 18 to 49 years, symptoms of flatulence, bloating or feeling of abdominal distention in the last three months with symptom onset at least six months prior to the study, normal abdominal examination, normal blood and stool tests including CBC, ESR, TSH, Ca, P, ALT, AST, Alph, BUN, Cr, FBS, TTGA, Stool exam (OB, OP, Leukocyte). Exclusion criteria :History of chronic or structural disorders of the gastrointestinal tract such as irritable bowel disease, peptic or duodenal ulcer disease, gastrointestinal obstruction, symptomatic gallbladder stone, serious clinical conditions, diabetes, thyroid gland disease, serious systemic disease (including heart , renal , lung and liver failure), uncontrollable high blood pressure, major psychiatric disorders, diagnosis of lactase deficiency or relieving symptoms by lactase free diet, alarm signs such as involuntarily weight loss more than 4.5 kg in the last three months, blood detection in the stool or melena or hemoptysis in the last three months, gastrointestinal surgery other than appendectomy, Hernioplasty, inguinal, abdominal wall surgery, cesarean section, hysterectomy and tubal ligation, masticatory disorders, cancer, drugs affecting the movement of the digestive tract such as surfactants, antispasmodic, osmotic laxatives, bulking agents, dopamine antagonists, muscarinic antagonist, 5HT4 and 5HT1 and 5HT3 agonists, antibiotics, opioids, anti-diarrheal medication, symbiotics, antimitotics (eg colchicine), anticholinergics, narcotics, antidepressants, anticonvulsants and any antiflatulance herbal medication two weeks before and during the study, taking antibiotics one month before starting the study, drug or alcohol abuse, lactating and pregnant women.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bloating, abdominal pain, flatulence, eructation, borborygmi, gas incontinence. Timepoint: before intervention, one month after starting the trial,one month after the end of trial. Method of measurement: Likert scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: one month after starting the trial. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Yazdian
Vice chancellor for research of Traditional Medicine Faculty of Tehran University of Medical Science
Outcome results
None listed